Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

N Am J Med Sci · 2011 · PMC3336907 · PMID 22540086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

The median survival of the Doxorubicin and PIAF groups was 6.83 months (95% confidence interval [95% CI], 4.80–9.56) and 8.67 months (95% CI, 6.36–12.00), respectively (P = 0.83), which failed to reach statistical significance for the study primary end point.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.